Peanut allergy is a common and potentially life-threatening condition caused by an immune system overreaction to peanut proteins. This allergy affects around 1 in 50 children globally and accounts for a significant percentage of severe food-related allergic reactions, including anaphylactic shock. There is a high unmet clinical need for better therapies, as current options, such as strict allergen avoidance and emergency epinephrine use, are inadequate for long-term management. The growing focus on innovative treatments, such as oral immunotherapy, biologics, and desensitization therapies, coupled with increasing research funding, is expected to drive significant advancements in the peanut allergy drug pipeline in the coming years.
The Peanut Allergy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into peanut allergy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for peanut allergy. The peanut allergy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The peanut allergy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with peanut allergy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to peanut allergy.
Peanut allergy is a hypersensitive immune reaction to peanut proteins, occurring when the immune system mistakenly identifies them as harmful. This leads to the release of chemicals like histamine, triggering symptoms ranging from mild hives to severe anaphylaxis. The growing pipeline includes innovative immunotherapies, biologics, and desensitization treatments aimed at providing long-term relief and reducing the risk of severe reactions. Continued research and development are critical in addressing this life-threatening condition.
Currently, peanut allergy treatments focus on allergen avoidance and managing symptoms during exposure, often with antihistamines or epinephrine auto-injectors. Emerging therapies include oral immunotherapy to desensitize patients and biologics targeting immune pathways to prevent reactions. These advancements promise improved safety and quality of life for individuals living with this allergy.
According to a report, the global prevalence of peanut allergy varies significantly, with the highest rates observed in Westernized countries like the United States and the United Kingdom, where 1-2% of the population is affected. In contrast, countries like France report lower rates (0.3-0.7%), while peanut allergy remains rare in Asia, where peanuts are less commonly identified as a primary allergen.
This section of the report covers the analysis of peanut allergy drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total peanut allergy clinical trials.
The drug molecule categories covered under the peanut allergy pipeline analysis include small molecules, biologics, immunotherapies, and peptide-based therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for peanut allergy.
The EMR peanut allergy drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in peanut allergy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for peanut allergy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of peanut allergy drug candidates.
The Phase 3 VITESSE study, sponsored by DBV Technologies, aims to evaluate the safety and efficacy of daily DBV712 (250 mcg) in desensitizing peanut-allergic children aged 4–7 years. This double-blind, placebo-controlled trial, involving around 600 participants, began in February 2023 and is expected to complete primary data collection by November 2025, with full study completion anticipated by October 2029.
Novartis Pharmaceuticals is sponsoring a Phase 2 study to evaluate remibrutinib’s efficacy, safety, and tolerability in adults with peanut allergies. The study involves an estimated 72 participants undergoing oral food challenges to assess tolerance to peanut protein. Scheduled for completion by March 8, 2025, this clinical trial aims to advance treatment options for this life-threatening condition.
IgGenix Australia Pty Ltd is sponsoring a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IGNX001 in peanut-allergic adults and older adolescents. This randomized, double-blind, placebo-controlled study involves about 24 participants. Initiated in September 2024, the study is expected to conclude by October 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Peanut Allergy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for peanut allergy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into peanut allergy collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share